Monographs: Pharmaceutical substances: Linezolid (Linezolidum)2024-01
Graphic formula.
Molecular formula. C16H20FN3O 4 Relative molecular mass. 337.4 Chemical name. N-({(5S)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (IUPAC); N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (CAS). CAS Registry Number. 165800-03-3. Description. A white to off-white powder. Solubility. Sparingly soluble in methanol R; soluble in dichloromethane R, slightly soluble in dehydrated ethanol R. Category. Antituberculosis. Storage. Linezolid should be kept in an airtight container, protected from light and moisture. Additional information. Linezolid may exhibit polymorphism. Requirements Manufacture. The production method is validated to demonstrate that genotoxic impurities are adequately controlled in the final product. Definition. Linezolid contains not less than 99.0% and not more than 101.0% of C16H20FN3O4, calculated with reference to the anhydrous substance. Identity tests
Water. Determine as described under 2.8 Determination of water by the Karl Fischer method, Method A. Use 0.300 g of the test substance. The water content is not more than 5.0 mg/g. Sulfated ash (2.3). Not more than 2.0 mg/g Heavy metals. Use 2.0 g of the test substance for the preparation of the test solution as described under 2.2.3 Limit test for heavy metals, Procedure 5. Determine the heavy metals content according to Method C; not more than 10 μg/g. Impurity E (linezolid R-isomer). Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm) packed with silica particles, the surface of which has been modified with chemically-bonded amylose tris-3,5-dimethylphenylcarbamate, (5 µm). As mobile phase, use a mixture of 960 volumes acetonitrile R, 40 volumes of dehydrated ethanol R, 1.6 volumes of trifluoroacetic acid R and 1 volume of n-butylamine R. Operate at a flow rate of 0.8 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 40 °C. Use a mixture of 960 volumes of acetonitrile R and 40 volumes of dehydrated ethanol R as diluent. For solution (1), dissolve 25.0 mg of the test substance and dilute to 50.0 mL. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. Dilute 1.0 mL of this solution to 10.0 mL. For solution (3), dissolve the content of a vial of linezolid impurity E RS with 1.0 mL of a solution of linezolid RS prepared at a nominal concentration of 0.025 mg/mL in a mixture of960 volumes of acetonitrile R and 40 volumes of dehydrated ethanol R. Inject 5 µL each of solutions (1), (2) and (3). Record the chromatograms for about two times the retention time of linezolid. In the chromatogram obtained with solution (3), impurity E is eluted with a relative retention of about 0.39 with reference to linezolid. The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peak of impurity E and the peak of linezolid is greater than 10. The test is also not valid unless, in the chromatogram obtained with solution (2), the peak due to linezolid is detected with a signal-to-noise ratio of at least 10. In the chromatogram obtained with solution (1):
Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm), packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (3.5 μm). Use the following conditions for gradient elution:
Prepare the phosphate buffer by dissolving 1.36 g of potassium dihydrogen phosphate R in 1000 mL of water R.
Operate with a flow rate of 1.2 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 25 °C. Prepare the following solutions in a mixture of 20 volumes of acetonitrile R and 80 volumes of phosphate buffer as diluent. For solution (1), dissolve 40.0 mg of the test substance in 50.0 mL. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3), dilute 1.0 mL of solution (2) to 10.0 mL. For solution (4), dissolve 5.0 mg each of linezolid RS, linezolid impurity A RS and linezolid impurity D RS and dilute to 100.0 mL. Inject 10 µL each of solutions (1), (2), (3) and (4). Use the chromatogram obtained with solution (4)to identify the peaks due to linezolid, impurity A and impurity D in the chromatogram obtained with solution (1). The impurity peaks, if present, are eluted at the following relative retention times with reference to linezolid (retention time about 17 minutes): impurity G about 0.49; impurity C about 0.59; impurity H about 0.75; impurity F about 0.80; impurity J about 1.28; impurity D about 1.36; impurity B about 1.42; impurity A about 1.50; impurity K about 1.53 and impurity I about 1.66 . The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peak due to impurity D and the peak due to impurity A is greater than 15.0. Also, the test is not valid unless, in the chromatogram obtained with solution (3), the peak due to linezolid is detected with a signal-to-noise ratio of at least 20. In the chromatogram obtained with solution (1):
Assay. Dissolve 0.250 mg of the test substance in 30 mL of glacial acetic acid R1, warming slightly if necessary, and titrate with perchloric acid (0.1 mol/L) VS, as described under 2.6 Non-aqueous titration, Method A. Each mL of perchloric acid (0.1 mol/L) VS is equivalent to 33.74 mg of C16H20FN3O4. Impurities
A. (5R)-5-(Azidomethyl)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-1,3-oxazolidin-2- one (linezolid azide)(synthesis related impurity),
B. N-({(5S)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide (thiolinezolide)(synthesis related impurity),
C. (5S)-5-(Aminomethyl)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-1,3-oxazolidin-2-one (linezolid amine) (synthesis related impurity, degradation product),
D. {(5R)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl methanesulfonate (synthesis related impurity),
E.N-({(5R)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (linezolid (R)-isomer) (synthesis related impurity),
F. N-({(5S)-3-[4-(Morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide (desfluoro linezolid)(synthesis related impurity),
G. 4-{4-[(5S)-5-(Acetamidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl}morpholin 4-oxide (linezolid N-oxide) (degradation product),
H. N-{(2R)-3-[3-Fluoro-4-(morpholin-4-yl)anilino]-2-hydroxypropyl}acetamide (degradation product),
I. 2-({(5S)-3-[3-Fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione (synthesis related impurity),
J. Ethyl [3-fluoro-4-(morpholin-4-yl)phenyl]carbamate (synthesis related impurity),
K. 2-{(2R)-3-[3-Fluoro-4-(morpholin-4-yl)anilino]-2-hydroxypropyl}-1H-isoindole-1,3(2H)-dione (synthesis related impurity). |